Skip to content

Vitamin D Supplementation and Pregnancy Outcomes

Evaluation and Comparison of the Efficacy of 1000 and 2000 IU/d Vitamin D Supplementation During Pregnancy on Maternal and Newborn Vitamin D Status and Pregnancy Outcomes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03308487
Enrollment
84
Registered
2017-10-12
Start date
2017-01-31
Completion date
2018-09-30
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maternal Vitamin D Status

Keywords

Vitamin D, pregnancy

Brief summary

Groups (group 1 receives 1000 IU vitamin D and group 2 receives 2000 IU vitamin D) through a random allocation. It is necessary to mention that all cases in each group could be able to receive the current supplementation during pregnancy (Folic acid, iron and multivitamin and calcium). This study aimed to evaluate the efficacy of two doses of vitamin D supplementation (1000 and 2000 IU/d) during pregnancy on maternal and newborn vitamin D status and metabolic profile including lipid profile (serum concentration of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride(TG)), glucose homeostasis (fasting glucose, insulin, insulin resistance (HOMA-IR)) and inflammatory and oxidative stress (OS) markers and pregnancy outcomes including gestational diabetes, preeclampsia, preterm delivery, abortion, cesarian section, and also anthropometric data and apgar score of infants compared with placebo.

Detailed description

In this randomized controlled trial, 84 pregnant women aged at 18-40 years with gestational age of \<12 weeks will be recruited and divided into 2 groups. Demographic, socioeconomic and lifestyle data as well as blood samples and urine samples will be collected at baseline and in the last month of pregnancy. Moreover the cord blood will be collected at birth. Fasting blood glucose, insulin resistance (HOMA-IR), insulin, lipid profile (serum concentration of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride(TG)), inflammatory (IL-1β, IL-6, TNF-α, hs-CRP) and oxidative stress markers (MDA, TAC), calcium:creatinine ratio are going to be evaluated at the beginning and in the end of the interventional period in pregnant women. Inflammatory (IL-1β, IL-6, Tumor Necrosis Factor (TNF-α), hs-CRP) and oxidative stress markers (MDA, TAC) will be determined in cord blood as well.

Interventions

DIETARY_SUPPLEMENTvitamin D3 (1000 IU)
DIETARY_SUPPLEMENTVitamin D3 (2000 IU)

Sponsors

National Nutrition and Food Technology Institute
CollaboratorOTHER
Tirang R. Neyestani, Ph.D.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* maternal age of 18-40 years, * gestational age of 12 weeks or less, * singleton pregnancies, * mothers supposed to have normal pregnancy and not having preexisting diseases like hypertension, or cardiac, renal, hepatic, autoimmune , rheumatoid arthritis and digestive disease, or endocrinological disorders including diabetes (type 1 or type 2 diabetes), parathyroid disorders, and thyroid disorder, * not receiving dietary supplements including vitamin D (\>600 IU/d), or omega-3 within the past 3 months before the intervention, * not taking medications that could potentially influence vitamin D metabolism, * willingness to participate in the study.

Exclusion criteria

* Participants who do not meet the inclusion criteria, * those who diagnosed to have fasting blood sugar (FBS)\>92 at first blood sampling and/or blood pressure \> 140/90 mmHg at the first visit, * using extra vitamin D3 supplement and/or omega-3 and/or other medications that could potentially influence vitamin D metabolism, * fetal anomaly, * poor adherence to the study protocol, * unwillingness to continue the intervention.

Design outcomes

Primary

MeasureTime frameDescription
The changes in maternal vitamin D status from first trimester to last month of pregnancybaseline and 6-8 monthsThe serum concentration of 25(OH) D will be measured during the first trimester and last month of pregnancy.

Secondary

MeasureTime frameDescription
The changes in serum concentration of insulin from first trimester to last month of pregnancybaseline and 6-8 monthsThe serum concentration of insulin will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of total cholesterol (TC) from first trimester to last month of pregnancybaseline and 6-8 monthsThe serum concentration of total cholesterol (TC) will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of low-density lipoprotein cholesterol (LDL-C) from first trimester to last month of pregnancybaseline and 6-8 monthsThe serum concentration of low-density lipoprotein cholesterol (LDL-C) will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of high-density lipoprotein cholesterol (HDL-C) from first trimester to last month of pregnancybaseline and 6-8 monthsThe serum concentration of high-density lipoprotein cholesterol (HDL-C) will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of triglyceride(TG) from first trimester to last month of pregnancybaseline and 6-8 monthsThe serum concentration of triglyceride(TG) will be measured during the first trimester and last month of pregnancy.
The changes in systolic blood pressure from first trimester to last month of pregnancybaseline and 6-8 monthssystolic and diastolic blood pressure will be measured by a training physician
The changes in diastolic blood pressure from first trimester to last month of pregnancybaseline and 6-8 monthssystolic and diastolic blood pressure will be measured by a training physician
preeclampsia2-5 monthsPreeclampsia characterized by high blood pressure begins after 20 weeks of pregnancy in women whose blood pressure had been normal.
Preterm delivery5-8 monthsA premature birth is a birth that takes place before the start of the 37th week of pregnancy.
Spontaneous abortion2-5 monthsSpontaneous abortion is the natural death of an embryo or fetus before 20 weeks of gestation.
The changes in cellular secretion of interleukin 1 from first trimester to last month of pregnancybaseline and 6-8 monthsThe status of interleukin 1 will be measured during the first trimester and last month of pregnancy.
The changes in cellular secretion of interleukin 6 from first trimester to last month of pregnancybaseline and 6-8 monthsThe status of interleukin 6 will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of fasting blood glucose from first trimester to last month of pregnancybaseline and 6-8 monthsThe serum concentration of fasting blood glucose will be measured during the first trimester and last month of pregnancy.
The changes in cellular secretion of TNF-a from first trimester to last month of pregnancybaseline and 6-8 monthsThe status of TNF-a will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of hs-CRP from first trimester to last month of pregnancybaseline and 6-8 monthsThe status of hs-CRP will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of MDA (Malondialdehyde) from first trimester to last month of pregnancybaseline and 6-8 monthsthe serum concentration of MDA (Malondialdehyde) will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of TAC from first trimester to last month of pregnancybaseline and 6-8 monthsthe serum concentration of TAC will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of parathyroid hormone (PTH) from first trimester to last month of pregnancybaseline and 6-8 monthsthe serum concentration of parathyroid hormone (PTH) will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of calcium from first trimester to last month of pregnancybaseline and 6-8 monthsthe serum concentration of calcium will be measured during the first trimester and last month of pregnancy.
The changes in serum concentration of phosphate from first trimester to last month of pregnancybaseline and 6-8 monthsthe serum concentration of phosphate will be measured during the first trimester and last month of pregnancy.
Apgar score6-8 monthsThe Apgar score is a quick evaluation of one minute and five minutes after birth which tests the birthing process and readiness of newborn to meet the world without additional medical assistance.
The weight measures of newborn6-8 monthsThe data of anthropometric measures including weight will be measured.
The height measures of newborn6-8 monthsThe data of anthropometric measures including height will be measured.
The head circumference measures of newborn6-8 monthsThe data of anthropometric measures including head circumference will be measured.
The changes in cellular secretion of interleukin 10 from first trimester to last month of pregnancybaseline and 6-8 monthsThe status of interleukin 10 will be measured during the first trimester and last month of pregnancy.

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026